1. Scrip
  2. >>R&D

Vical Faced With Failure of Another Vaccine Trial

 
• By Emily Hayes

Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.

Arrows miss target

Vical Inc. will have to refocus its development efforts once again, with the mid-stage trial failure of its genital herpes therapeutic vaccine VCL-HB01. The company is ceasing development of the candidate and will put that capital toward development of its novel antifungal agent.

The herpes simplex virus (HSV)-2 vaccine candidate, developed with the company's proprietary Vaxfectin adjuvant, did not meet the primary endpoint...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.